Finance

Lists
EWL:ETR
Edwards Lifesciences Corp
74,50 €
+1,14%
(+0,84) 1D
9 ოქტ, 17:35:37 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EWL...
Open
74,58 €
High
75,14 €
Low
74,50 €
Mkt. cap
49,12 მლრდ.
Avg. vol.
61,00
Volume
6,00
52-wk high
84,00 €
52-wk low
62,00 €
No. of employees
16 ათ.
Open
74,58 €
High
75,14 €
Low
74,50 €
Mkt. cap
49,12 მლრდ.
Avg. vol.
61,00
Volume
6,00
52-wk high
84,00 €
52-wk low
62,00 €
No. of employees
16 ათ.
News stories
From web sources and news partners
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees16 ათ.
Founded1958
Headquartersირვაინი, კალიფორნია, ამერიკის შეერთებული შტატები
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,55 მლრდ.
1,57 მლრდ.
1,65 მლრდ.
1,74 მლრდ.
Cost of goods sold
345,20 მლნ.
343,00 მლნ.
362,60 მლნ.
392,40 მლნ.
Cost of revenue
345,20 მლნ.
343,00 მლნ.
362,60 მლნ.
392,40 მლნ.
Research and development expenses
280,70 მლნ.
267,70 მლნ.
263,30 მლნ.
278,90 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514,60 მლნ.
601,20 მლნ.
522,20 მლნ.
561,20 მლნ.
Operating expense
782,80 მლნ.
854,60 მლნ.
771,30 მლნ.
829,10 მლნ.
Total operating expenses
1,13 მლრდ.
1,20 მლრდ.
1,13 მლრდ.
1,22 მლრდ.
Operating income
425,10 მლნ.
372,00 მლნ.
514,70 მლნ.
519,50 მლნ.
Other non operating income
1,10 მლნ.
2,30 მლნ.
69,90 მლნ.
-25,00 მლნ.
EBT including unusual items
348,40 მლნ.
90,40 მლნ.
459,00 მლნ.
519,80 მლნ.
EBT excluding unusual items
444,50 მლნ.
464,00 მლნ.
603,60 მლნ.
511,10 მლნ.
Income tax expense
56,10 მლნ.
26,20 მლნ.
78,30 მლნ.
278,40 მლნ.
Effective tax rate
16,10%
28,98%
17,06%
53,56%
Other operating expenses
-12,50 მლნ.
-14,30 მლნ.
-14,20 მლნ.
-11,00 მლნ.
Net income
291,10 მლნ.
91,20 მლნ.
380,70 მლნ.
241,90 მლნ.
Net profit margin
18,74%
5,81%
23,09%
13,89%
Earnings per share
0,67
0,58
0,78
0,78
Interest and investment income
16,70 მლნ.
114,20 მლნ.
17,40 მლნ.
15,00 მლნ.
Interest expense
-
-20,40 მლნ.
-
-
Net interest expenses
16,70 მლნ.
93,80 მლნ.
17,40 მლნ.
15,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
464,30 მლნ.
414,70 მლნ.
555,60 მლნ.
562,20 მლნ.
Gain or loss from assets sale
-
-33,90 მლნ.
-
-
AI content may include mistakes. Learn more
Google აპები